April 02, 2012
A federal judge dismissed a consolidated class action Friday accusing Genzyme Corp. of misleading the U.S. Food and Drug Administration and selling its securities at artificially inflated prices, saying alleged misstatements to the FDA weren't enough to show Genzyme intended to deceive investors.